Eli Lilly, a pharmaceutical company, completed the acquisition of DICE Therapeutics, a biopharmaceutical company, for $2.4bn. "In combination with its novel technology and expertise in drug discovery, DICE's talented workforce and passion for innovation will enhance our efforts to make life better for people living with devastating autoimmune diseases. We welcome DICE colleagues to Lilly and, together, we can tackle the challenges ahead in finding new treatments for patients with significant unmet medical needs," Patrik Jonsson, Eli Lilly EVP.